This study is a single-center, open label, 4-month study, designed to evaluate the safety and treatment efficacy of RBM-007 in patients with intraretinal or subretinal edema due to previously untreated neovascular AMD. Up to 5 subjects will be randomized to receive study medication. Study treatment will be administered by intravitreal injections.

开始日期2021-06-15

申办/合作机构-

100 项与 Umedaptanib pegol 相关的临床结果

登录后查看更多信息

100 项与 Umedaptanib pegol 相关的转化医学

登录后查看更多信息

100 项与 Umedaptanib pegol 相关的专利（医药）

登录后查看更多信息

项与 Umedaptanib pegol 相关的文献（医药）

2024-04-01·Eye (London, England)

Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients

Article

作者: Bezwada, Padma ; Sakota, Eri ; Pereira, Daniel S ; Nakamura, Yoshikazu ; Nishihata, Toshiaki ; Mahesh, Vinaya ; Bhisitkul, Robert B ; Maturi, Raj K ; Nakamura, Emiko ; Akita, Kazumasa ; Ali, Yusuf

Abstract:

Background/Objective:

Intravitreal injections of anti-vascular endothelial growth factor (VEGF) agents are the first-line treatment for exudative age-related macular degeneration (nAMD). Due to the limitations of these standard therapies, targeting alternative mechanisms of action may be helpful for treatment of this very common disease. Here, we investigated an anti-fibroblast growth factor-2 (FGF2) aptamer, umedaptanib pegol, a next generation therapeutic for the treatment of nAMD.

Methods:

Three phase 2 studies were designed. First, a multicentre, randomized, double-masked TOFU study assessed the efficacy of intravitreal injections of umedaptanib pegol monotherapy or in combination with aflibercept, compared to aflibercept monotherapy in 86 subjects with anti-VEGF pretreated nAMD. Second, 22 subjects who had exited the TOFU study received 4 monthly intravitreal injections of umedaptanib pegol (extension, RAMEN study). Third, as an investigator-sponsored trial (TEMPURA study), a single-center, open-label, 4-month study was designed to evaluate the safety and treatment efficacy of umedaptanib pegol in five naïve nAMD patients who had not received any prior anti-VEGF treatment.

Results:

The TOFU study demonstrated that umedaptanib pegol alone or in combination with aflibercept did not improve best-corrected visual acuity (BCVA) and central subfield thickness (CST) over aflibercept alone. However, the change in BCVA and CST at primary endpoint was marginal in all the three treatment groups, suggesting that umedaptanib pegol is effective to prevent the disease progression. The RAMEN study confirmed the cessation of disease progression. In the TEMPURA study, naïve nAMD patients showed improvement and no further macular degeneration, with striking improvement of visual acuity and central subfield thickness in some of the patients.

Conclusions:

These results demonstrate, for the first time, clinical proof of concept for aptamer based anti-FGF2 therapy of nAMD.

2023-01-01·International journal of nanomedicine

Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology.

Review

作者: Zhang, Feng ; Cao, Jiamin ; Xiong, Wei

Aptamers are widely applied to diagnosis and therapy because of their targeting. However, the current progress of research into aptamers for the treatment of eye disorders has not been well-documented. The current literature on aptamers was reviewed in this study. Aptamer-related drugs and biochemical sensors have been evaluated for several eye disorders within the past decade; S58 targeting TGF-β receptor II and pegaptanib targeting vascular endothelial growth factor (VEGF) are used to prevent fibrosis after glaucoma filtration surgery. Anti-brain-derived neurotrophic factor aptamer has been used to diagnose glaucoma. The first approved aptamer drug (pegaptanib) has been used to inhibit angiogenesis in age-related macular degeneration (AMD) and diabetic retinopathy (DR), and its efficacy and safety have been demonstrated in clinical trials. Aptamers, including E10030, RBM-007, AS1411, and avacincaptad pegol, targeting other angiogenesis-related biomarkers have also been discovered and subjected to clinical trials. Aptamers, such as C promoter binding factor 1, CD44, and advanced end products in AMD and DR, targeting other signal pathway proteins have also been discovered for therapy, and biochemical sensors for early diagnosis have been developed based on aptamers targeting VEGF, connective tissue growth factor, and lipocalin 1. Aptamers used for early detection and treatment of ocular tumors were derived from other disease biomarkers, such as CD71, nucleolin, and high mobility group A. In this review, the development and application of aptamers in eye disorders in recent years are systematically discussed, which may inspire a new link between aptamers and eye disorders. The aptamer development trajectory also facilitates the discovery of the pathogenesis and therapeutic strategies for various eye disorders.

2019-09-01·Molecular therapy. Nucleic acids

Anti-Angiogenic and Anti-Scarring Dual Action of an Anti-Fibroblast Growth Factor 2 Aptamer in Animal Models of Retinal Disease

Article

作者: Fujiwara, Masatoshi ; Nakamura, Yoshikazu ; Nishihata, Toshiaki ; Bhisitkul, Robert B ; Nonaka, Yosuke ; Imai, Hirotaka ; Futakawa, Satoshi ; Ali, Yusuf ; Matsuda, Yusaku ; Akita, Kazumasa

Currently approved therapies for age-related macular degeneration (AMD) are inhibitors against vascular endothelial growth factor (VEGF), which is a major contributor to the pathogenesis of neovascular AMD (nAMD). Intravitreal injections of anti-VEGF drugs have shown dramatic visual benefits for AMD patients. However, a significant portion of AMD patients exhibit an incomplete response to therapy and, over the extended management course, can lose vision, with the formation of submacular fibrosis as one risk factor. We investigated a novel target for AMD treatments, fibroblast growth factor 2 (FGF2), which has been implicated in the pathophysiology of both angiogenesis and fibrosis in a variety of tissue and organ systems. The anti-FGF2 aptamer, RBM-007, was examined for treatment of nAMD in animal models. In in vivo studies conducted in mice and rats, RBM-007 was able to inhibit FGF2-induced angiogenesis, laser-induced choroidal neovascularization (CNV), and CNV with fibrosis. Pharmacokinetic studies of RBM-007 in the rabbit vitreous revealed high and relatively long-lasting profiles that are superior to other approved anti-VEGF drugs. The anti-angiogenic and anti-scarring dual action of RBM-007 holds promise as an additive or alternative therapy to anti-VEGF treatments for nAMD.

项与 Umedaptanib pegol 相关的新闻（医药）

2023-12-05

·Business Wire

RIBOMIC Phase I and II Data Published in the Eye: Full TOFU/RAMEN/TEMPURA Trial Results Demonstrate Clinical Proof of Concept of Umedaptanib Pegol in Exudative Age-Related Macular Degeneration (nAMD)

TOKYO--( BUSINESS WIRE )--RIBOMIC Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TOKYO:4591), today announced that the Eye has published full results from the phase 1 (SUSHI) and phase 2 (TOFU/RAMEN/TEMPURA) trials evaluating the efficacy and safety of intravitreal umedaptanib pegol in nAMD 1,2 . TOFU is a randomized, double-masked study assessing the efficacy of intravitreal umedaptanib pegol monotherapy or in combination with Eylea®, compared to Eylea® monotherapy in 86 subjects with anti-VEGF pretreated nAMD. RAMEN is an extension study of TOFU, in which 22 subjects who had exited the TOFU study received 4 monthly intravitreal injections of umedaptanib pegol. TEMPURA is an investigator-sponsored, single-center, open-label, 4-month study of umedaptanib pegol in five treatment-naïve nAMD patients. Throughout these studies umedaptanib pegol was safe, well tolerated, and effective to treat nAMD patients with no or short history of anti-VEGF treatment. Striking improvements in visual acuity and anatomy were observed in some of the treatment naïve patients. In nAMD patients with a long history of anti-VEGF treatment, umedaptanib pegol showed no additional benefit of monotherapy or the combination over Eylea®. Nevertheless, the pre-existing fibrosis remained stable without worsening in these studies. Notably, visual acuity decreased slightly in patients who switched from anti-VEGF (Eylea®) to umedaptanib pegol in the RAMEN study. Therefore, we believe that umedaptanib pegol is an excellent alternative as a first-line medication before patients are exposed to anti-VEGF treatments to mitigate risk of damage caused by fibrosis. Further studies are needed on the efficacy of umedaptanib pegol early in the onset of nAMD as well as in coordination or combination with anti-VEGF drugs. “We are very pleased that The Royal College of Ophthalmologists journal ( Eye ) recognized the trial results as a viable Proof-of-Concept for umedaptanib pegol in nAMD therapy. This first clinical evidence is an exciting breakthrough which raises hope that a non-VEGF target can lead to successful monotherapy in nAMD and provide a first-line alternative to treatment naïve nAMD patients.” commented Yoshi Nakamura, Ph.D., the CEO of RIBOMIC Inc. References 1 Pereira, D.S., Akita, K., Bhisitkul, R.B., Nishihata, T., Ali, Y., Nakamura, E., Nakamura, Y.: Safety and tolerability of intravitreal umedaptanib pegol (anti-FGF2) for neovascular age-related macular degeneration (nAMD): a phase 1, open label study. Eye, published online: 01 December 2023. URL: https://www-nature-com.libproxy1.nus.edu.sg/articles/s41433-023-02849-6.pdf 2 Pereira, D.S., Maturi, R.K., Akita, K., Bhisitkul, R.B., Nishihata, T., Sakota, E., Ali, Y., Nakamura, E., Bezwada, P., Nakamura, Y.: Clinical proof of concept for anti-FGF2 therapy in exudative age-related macular degeneration (nAMD): phase 2 trials in treatment-naïve and anti-VEGF pretreated patients. Eye, published online: 30 November 2023. URL: https://www-nature-com.libproxy1.nus.edu.sg/articles/s41433-023-02848-7.pdf About Umedaptanib Pegol Umedaptanib pegol is a novel oligonucleotide-based aptamer formerly called RBM-007 with potent anti-FGF2 (fibroblast growth factor 2) activity. FGF2 is implicated in not only angiogenesis but also fibrosis in several diseases including nAMD. The dual action of umedaptanib pegol (anti-angiogenic and anti-scarring) holds promise as an additive or alternative therapy to anti-VEGF treatments for nAMD. The three completed Phase 2 studies in nAMD are: 1. Active-controlled, double masked trial, TOFU study (NCT04200248); 2. Single-arm, open-label extension trial, RAMEN (NCT04640272); and 3. Investigator sponsored trial with treatment naïve nAMD patients, the TEMPURA study (NCT04895293). About Exudative Age-Related Macular Degeneration Exudative age-related macular degeneration (nAMD), is the leading cause of blindness in the United States and Europe. It is caused by the formation of abnormal and leaky new blood vessels under the retina, termed choroidal neovascularization. The leakage of fluid from the vessels causes retinal thickening and retinal degeneration including fibrotic scar formation, and leads to severe and rapid loss of vision. ABOUT RIBOMIC RIBOMIC is a clinical stage bio-pharmaceutical company specializing in the discovery and development of aptamer therapeutics, which is one type of nucleic acid medicine, a field with much potential for the development of next-generation drugs. The RiboART system, the company’s core drug discovery platform, can be used for the discovery of many types of aptamer drugs. RIBOMIC is dedicated to the discovery and development of drugs that target the broad field of unmet medical needs, which encompasses eye disorders, rare disease of short stature in children and many other diseases. See RIBOMIC website for more information. https://www.ribomic.com/eng/ Forward-Looking Statements This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company’s current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and discontinuation of clinical trials, v) infringement of Company’s intellectual property rights by third parties. Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice. "RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

临床1期临床结果临床2期

2022-11-17

·IQVIA艾昆纬

曙光初现：盘点RNA疗法的4大运用

导读RNA疗法是一种使用基于RNA分子来治疗或预防特定疾病的新疗法。随着mRNA COVID-19疫苗获得紧急授权并正式投入使用，RNA药物成为了研发新热点。纯化和细胞传递方面的进步使mRNA疗法得以广泛应用。与传统药物相比，RNA疗法具有成本效益高、易生产等优势。目前主要的 RNA 疗法包括：反义寡核苷酸、小干扰RNA（siRNA）、mRNA以及核酸适配体。本文将利用IQVIA Pipeline Intelligence数据库，回顾RNA疗法的最新进展。1RNA疗法在肿瘤治疗中的运用随着科学家对以寡核苷酸或siRNA为基础的靶向非编码RNA展现出越来越多的兴趣，RNA疗法在癌症领域的探索再度兴起。非编码RNA的优势在于其具有肿瘤特异性，即只在肿瘤中具有活性。Sirnaomics的cotsiranib (STP 705)是一种抑制TGF-Beta1和COX-2基因表达的双重靶点siRNA治疗方法，用于非黑色素瘤皮肤癌，包括鳞状细胞癌，基底细胞癌和肝癌的治疗。2022年2月，Sirnaomics公布了cotsiranib治疗皮肤基底细胞癌II期临床试验的中期数据。数据显示，剂量范围在30至90微克之间的患者，其剂量反应实现了完全应答，且无明显的皮肤不良反应。研发人员也在积极探索将mRNA疫苗技术应用于癌症的治疗干预，并设计为肿瘤相关抗原的表达，用于诱导细胞介导的免疫反应，以摧毁癌细胞。目前有两种mRNA疫苗正处于Ⅱ期临床试验阶段。默克和Moderna合作研发的mRNA 4157是一种基于mRNA的个性化癌症疫苗，通过引导患者的细胞表达选定的新表位，刺激免疫系统更好地识别并消灭癌细胞。该疫苗正处于Ⅱ期临床试验，验证与pembrolizumab联合用于治疗高风险的黑色素瘤患者，预计将于2023年12月完成。基因泰克和BioNTech研发的基于mRNA的个体化癌症疫苗autogene cevumeran（RG 6180；BNT 122）编码了20个来自患者的特异性肿瘤新抗原，以诱导针对肿瘤的强大免疫反应。该疫苗正作为一线治疗药物与pembrolizumab联合使用，对未经治疗的晚期黑色素瘤患者进行II期临床试验。同时，对将其作为替代II期（高风险）或III期手术切除结直肠癌的治疗模式的II期试验正在进行中。2RNA疗法在传染性疾病治疗中的运用BioNTech/辉瑞和Moderna的COVID-19疫苗是最早进入市场的两种mRNA疫苗。2020年12月11日，美国FDA紧急授权使用辉瑞和BioNTech共同研发的mRNA新冠疫苗tozinameran。Tozinameran采用LNP递送技术，由编码SARS-CoV-2的突变针刺蛋白的核苷修饰的mRNA组成，并于2021年8月23日被FDA正式批准用于预防16岁及以上人群的新冠肺炎。该疫苗随后在全球范围获得了100多个监管机构的批准。Moderna公司的elasomeran（SPIKEVAX；mRNA 1273）是一种由脂质纳米粒子包裹的RNA链组成的mRNA疫苗，编码一种预融合稳定形势的刺突SARS-CoV-2蛋白，已在美国、英国、欧盟、澳大利亚、加拿大、韩国和瑞士获批用于预防18岁及以上人群的新冠肺炎。该疫苗获得了韩国的附条件批准，并获得了多个国家的紧急使用授权，包括美国、日本和印度。3RNA疗法在心血管代谢性疾病治疗中的应用在过去十年中，研究人员已发现，部分RNA有助于调控心血管疾病，抑制胆固醇的形成、胆固醇斑块的堆积和心脏病发作后导致的细胞死亡。RNA疗法正作为一种治疗心血管代谢疾病的方法迅速崛起。Alnylam公司的patisiran（ONPATTRO）是一种针对转甲状腺素（TTR）的RNAi疗法，利用Arbutus公司专有的脂质纳米粒子技术，是第一个获得美国FDA批准的RNAi疗法，于2018年上市，用于治疗遗传性转甲状腺素介导的（hATTR）淀粉样变性引起的多发性神经病。Patisiran旨在通过抑制TTR蛋白的合成来使TTR mRNA沉默，并防止TTR淀粉样蛋白在组织中进一步积累。Patisiran也已在加拿大、欧盟和巴西获得批准。4RNA疗法在眼科疾病领域的应用眼科疾病领域是RNA疗法的另一个发展领域，基因沉默疗法在该领域中显示出良好表现。ProQR的ultevursen (QR 421a)是一种基于RNA的寡核苷酸药物，旨在治疗USH2A基因13号外显子突变引起的Usher综合征Ⅱ型和非综合征性视网膜色素变性。Ultevursen与突变的USH2A RNA结合，并通过外显子跳转方法将13号外显子从RNA中排除，使视网膜细胞能够产生一种略微缩短但功能正常、且对视觉至关重要的usherin蛋白的表达。目前，针对这些适应症的II/III期临床试验正在进行中。此外，还有两个项目的Ⅱ期试验也在进行中。Ionis的IONIS-FB-LRx是一种使用Ionis LICA技术设计的反义药物，旨在减少补体先天免疫系统中的关键蛋白补体因子B的产生。Ribomic的RBM 007是一种基于寡核苷酸的抗FGF2（成纤维细胞生长因子2）适体，能够同时抑制血管生成及视网膜中的瘢痕形成。总结 RNA疗法已成为治疗多种疾病的有效方式，为靶向致病基因表达模式提供了更多选择，具有可高效生产、可提供长期疗效，可降低基因毒性风险的特点，2020年首次获批用于预防COVID-19的mRNA疫苗就是一个成功案例。技术创新有助于扩大RNA疗法的应用范围，推进mRNA等复杂核酸模板的使用，造福更多患者。

信使RNA临床2期siRNA疫苗寡核苷酸

2022-06-13

·PRNewswire

The Age-related macular degeneration market growth is expected to boost owing to the expected launch of therapies, increasing prevalence of Age-related macular degeneration, development in the field of gene therapy, patient-friendly dosage regimes, and several other factors during the forecast period. LAS VEGAS, June 13, 2022 /PRNewswire/ -- DelveInsight's Age-related Macular Degeneration Market Insights report includes a comprehensive understanding of current treatment practices, Age-related macular degeneration emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. Key Takeaways from the Age-related Macular Degeneration Market Report As per DelveInsight analysis, the Age-related macular degeneration market size in the 7MM was approximately USD 9.8 billion in 2021. As per DelveInsight estimation, the Dry AMD market size was approximately USD 1,377 million, and the Wet AMD market size was approximately USD 8,463 million, which is further expected to increase by 2032. As per the estimates, the total Age-related macular degeneration prevalent cases in the 7MM was approximately 51.7 million in 2021. Leading Age-related macular degeneration companies Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others are developing novel Age-related Macular Degeneration drugs which can be available in the Age-related Macular Degeneration market in the upcoming years. The Wet Age-related macular degeneration therapies in the pipeline include OPT-302, KSI-301, RGX-314, AKST4290, GB-102 (Sunitinib Malate), RBM-007, Lytenava (Bevacizumab-vikg), UBX1325, PAN-90806, CLS-AX (Axitinib), and others. The Dry Age-related Macular Degeneration therapies in the pipeline include Danicopan (ALXN2040), EG-301, RG6147 (RO7171009), ALK-001, Elamipretide, OpRegen, CPCB-RPE1, Luminate (Risuteganib), ANX007, NGM621, LNP023 (Iptacopan), IONIS-FB-LRx, Pegcetacoplan, Zimura (Avacincaptad Pegol), GT005, RPESC-RPE-4W, GEM103, and others. The expected launch of therapies and the increasing prevalence will lead to Age-related macular degeneration market growth during the forecast period. Discover more about therapies set to grab major age-related macular Degeneration market share @ Age-related Macular Degeneration Market Landscape Age-related Macular Degeneration Overview Age-related macular degeneration (AMD) is a leading cause of severe, irreversible blindness in developed countries around the world, with a significant impact on the quality of life of the affected people. With the current expensive standard of care, the increase in Age-related macular degeneration life expectancy brings an increase in the number of reported cases, putting major stress on health care systems. Age-related macular degeneration (AMD) can also be characterized as either dry Age-related macular degeneration (atrophic or non-neovascular) or wet Age-related macular degeneration (exudative or neovascular). The most common Age-related macular degeneration symptoms include blurry or fuzzy vision, loss of central vision, difficulty in recognizing familiar faces, and others. Visual acuity test, pupil dilation, fluorescein angiography, Amsler grid, and others are the following tests used for Age-related macular degeneration diagnosis. Age-related Macular Degeneration Epidemiology Segmentation As per DelveInsight, there were approx 51.7 million Age-related macular degeneration prevalent cases in the 7MM in 2021. Among the total diagnosed cases of Age-related macular degeneration, the highest cases were observed for dry Age-related macular degeneration in 2021. The Age-related macular degeneration market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalent Cases of Age-related Macular Degeneration Total Diagnosed Prevalent Cases of Age-related Macular Degeneration Type-specific Diagnosed Prevalent Cases of AMD Total Age-specific Cases of Wet AMD, and Dry AMD Total Diagnosed Dry AMD Cases by Stages Total Geographic Atrophy Cases Associated With Dry AMD by Visual Impairment Download the report to understand which factors are driving Age-related macular degeneration epidemiology trends @ Age-related Macular Degeneration Epidemiological Insights Wet Age-related Macular Degeneration Treatment Market Photodynamic therapy, which employed an intravenous drug (injected into a vein) and laser to seal off bleeding blood vessels, was the best available Age-related macular degeneration treatment fifteen years ago. However, improvements in medical research have revealed VEGF as a critical pathophysiological factor in the development of neovascular AMD, with an important involvement in angiogenesis, vascular permeability, and inflammatory response. Anti-VEGF intravitreal injections have provided a new therapeutic window in the wet AMD treatment, effectively stopping the pathophysiological process of AMD and restoring retinal shape and function. Anti-VEGF therapies such as ranibizumab, aflibercept (Eylea), brolucizumab (Beovu), and faricimab (Vabysmo) are intravitreal injections given for wet AMD treatment. Though existing anti-VEGF therapies have transformed the way wet AMD is treated and greatly improved the lives of many patients, they will face stiff competition from new biosimilars and off-label drugs when their patents expire in the coming years. Furthermore, current anti-VEGF therapies have several unmet needs. Dry Age-related Macular Degeneration Treatment Market Currently, there is no approved dry AMD treatment, and there is a significant unmet need for a therapy to decrease its progression. Dry AMD's pathogenesis is poorly known. On the other hand, failure to achieve the primary outcomes may be due to the advanced stage of the disease rather than a lack of action on appropriate targets. Several pharmaceutical companies are currently working on developing novel therapies for dry AMD treatment. The therapies in the dry AMD pipeline include Pegcetacoplan (Apellis Pharmaceuticals), Zimura (Iveric bio), RO7171009; RG6147 (Genentech), IONIS-FB-LRx (Ionis Pharmaceuticals/ Roche), Luminate (Allegro Ophthalmics), NGM621 (NGM Biopharmaceuticals), Elamipretide (Stealth BioTherapeutics), CPCB-RPE1 (Regenerative Patch Technologies), OpRegen (CellCure Neurosciences/Lineage Cell Therapeutics/ Roche), GT005 (Gyroscope Therapeutics), and others. These therapies come with different types of mechanisms of action, including C3 inhibitor, C5 inhibitor, Integrin Inhibitors, Anti-C1q antibody, Anti-C3 antibody, Factor D inhibitor, HtrA1, ASO Complement Factor B, and others. Two C3 inhibitors, NGM621 (NGM Biopharmaceuticals) and pegcetacoplan (Apellis Pharmaceuticals), and one C5 inhibitor, Zimura (Iveric Bio), are showing promise as prospective treatments to slow the course of geographic atrophy. To know more about Age-related macular degeneration treatment visit @ Age-related Macular Degeneration Treatment Guidelines Wet Age-related Macular Degeneration Pipeline Therapies and Key Companies OPT-302: Opthea Limited KSI-301: Kodiak Sciences Inc. RGX-314: REGENXBIO AKST4290: Alkahest Inc GB-102 (Sunitinib Malate): Graybug Vision RBM-007: Ribomic USA Inc Lytenava (Bevacizumab-vikg): Outlook Therapeutics, Inc. UBX1325: Unity Biotechnology, Inc PAN-90806: PanOptica, Inc. CLS-AX (Axitinib): Clearside Biomedical Others Dry Age-related Macular Degeneration Pipeline Therapies and Key Companies Danicopan (ALXN2040): Alexion Pharmaceuticals and AstraZeneca EG-301: Evergreen Therapeutics RG6147 (RO7171009): Roche (Genentech) ALK-001: Alkeus Pharmaceuticals Elamipretide: Stealth BioTherapeutics OpRegen: CellCure Neurosciences CPCB-RPE1: Regenerative Patch Technologies Luminate (Risuteganib): Allegro Ophthalmics ANX007: Annexon Biosciences NGM621: NGM Biopharmaceuticals LNP023 (Iptacopan): Novartis IONIS-FB-LRx: Ionis Pharmaceuticals Pegcetacoplan: Apellis Pharmaceuticals Zimura (Avacincaptad Pegol): Iveric Bio GT005: Gyroscope Therapeutics and Novartis RPESC-RPE-4W: Luxa Biotechnology GEM103: Gemini Therapeutics Others Learn more about the dry AMD treatments in clinical trials @ New Treatment for Dry AMD Wet Age-related Macular Degeneration Market Dynamics The rising prevalence of wet AMD and the growing geriatric population are two significant factors driving the growth of the wet AMD market. Moreover, the wet AMD market dynamics are changing as extensive research and development have helped understand the histopathology and pathophysiology of wet AMD. Development in the field of gene therapy and a robust pipeline are also propelling the wet AMD market growth. However, some factors restrain the growth of the wet AMD market. Patients do not contact a physician until they have intermediate to severe AMD symptoms, making timely diagnosis extremely difficult. Moreover, the high cost of therapy, with gene therapy costing over USD 400,000, presents a significant barrier to treatment availability. In addition, the competitive treatment landscape and emerging biosimilars may also limit the growth of the wet AMD market. Dry Age-related Macular Degeneration Market Dynamics The dry AMD market is still untapped. The enormous and growing patient pool with no approved or adequate therapies provides companies with attractive prospects; the estimated potential is similar to wet AMD. Moreover, the dry AMD pipeline includes peptide derivatives, antibodies, antisense oligonucleotides, stem cell treatment, and gene therapy that function on various mechanisms such as C1q, C3, and C5 inhibitors, cell replacements, HtrA Serine Peptidase 1 inhibitor, and others. The launch of these therapies will boost the dry AMD market growth. Furthermore, the increasing prevalence of dry AMD is also driving the dry AMD market forward. However, limited knowledge of pathophysiology, disease severity, and consequences affect the development of efficacious treatment for dry AMD. Moreover, emerging gene therapies and stem cell therapies for dry AMD may face hurdles in access and reimbursement due to their anticipated high cost and will restrain the growth of the dry AMD market. Scope of the Age-related Macular Degeneration Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Age-related Macular Degeneration Companies: Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc., REGENXBIO, Alkahest Inc, Graybug Vision, Ribomic USA Inc, Outlook Therapeutics, Inc., Unity Biotechnology, Inc, PanOptica, Inc., Clearside Biomedical, Alexion Pharmaceuticals, AstraZeneca, Evergreen Therapeutics, Alkeus Pharmaceuticals, Stealth BioTherapeutics, CellCure Neurosciences, Regenerative Patch Technologies, Allegro Ophthalmics, Annexon Biosciences, NGM Biopharmaceuticals, Ionis Pharmaceuticals, Apellis Pharmaceuticals, Iveric Bio, Gyroscope Therapeutics, Luxa Biotechnology, Gemini Therapeutics, and others Key Wet Age-related Macular Degeneration Therapies: OPT-302, KSI-301, RGX-314, AKST4290, GB-102 (Sunitinib Malate), RBM-007, Lytenava (Bevacizumab-vikg), UBX1325, PAN-90806, CLS-AX (Axitinib), and others Key Dry Age-related Macular Degeneration Therapies: Danicopan (ALXN2040), EG-301, RG6147 (RO7171009), ALK-001, Elamipretide, OpRegen, CPCB-RPE1, Luminate (Risuteganib), ANX007, NGM621, LNP023 (Iptacopan), IONIS-FB-LRx, Pegcetacoplan, Zimura (Avacincaptad Pegol), GT005, RPESC-RPE-4W, GEM103, and others Therapeutic Assessment: Age-related Macular Degeneration current marketed and emerging therapies Age-related Macular Degeneration Market Dynamics: Age-related Macular Degeneration market drivers and barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Unmet Needs, KOL's views, Analyst's views, Age-related Macular Degeneration Market Access and Reimbursement Discover more about Age-related macular degeneration drugs in development @ Age-related Macular Degeneration Clinical Trials Table of Contents Get in touch with our Business executive @ Healthcare Due Diligence Services Related Reports Age-related Macular Degeneration Epidemiology Age-related Macular Degeneration Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Age-related Macular Degeneration epidemiology in the 7MM. Age-related Macular Degeneration Pipeline Age-related Macular Degeneration Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Age-related Macular Degeneration companies including Regeneron Pharmaceuticals, Novartis, Roche, Opthea Limited, Kodiak Sciences Inc. , among others. Wet Age-related Macular Degeneration Market Wet Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Wet Age-related Macular Degeneration companies including Alkahest Inc, Graybug Vision, Clearside Biomedical, among others. Dry Age-related Macular Degeneration Market Dry Age-related Macular Degeneration Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Dry Age-related Macular Degeneration companies including Alkeus Pharmaceuticals, Dobecure, Iveric Bio, among others. Wet Age-related Macular Degeneration Pipeline Wet Age-related Macular Degeneration Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Wet Age-related Macular Degeneration companies including Opthea Limited, Kodiak Sciences Inc., REGENXBIO, among others. Dry Age-related Macular Degeneration Pipeline Dry Age-related Macular Degeneration Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Dry Age-related Macular Degeneration companies including Allergo Ophthalmics, Gyroscope Therapeutics, Gemini Therapeutics, among others. Other Trending Reports Periodontal Disease Market | Open-Angle Glaucoma Market | Obsessive-Compulsive Disorder Market | Nicotine Addiction Market | Nephrosclerosis Market | Muscle Invasive Bladder cancer Market | Mucinous cystic neoplasms Market | Metastatic Uveal Melanoma Market | ICOS-Next Generation Immunotherapy Market | Herpes Simplex Market | Hepatitis C Market | Guillain-Barre Syndrome Market | Graft Versus Host Disease Market | Goitre Market Related Healthcare Blogs Dry AMD Market: Pegcetacoplan vs Zimura Wet Age-related Macular Degeneration Market Outlook Eye Disorders Treatment Market About DelveInsight DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve . Connect with us on LinkedIn |Facebook|Twitter Contact Us Shruti Thakur [email protected] +1(919)321-6187 Logo: SOURCE DelveInsight Business Research, LLP

基因疗法抗体生物类似药寡核苷酸细胞疗法

100 项与 Umedaptanib pegol 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
湿性年龄相关性黄斑变性	临床2期	美国	RIBOMIC USA, INC.	2019-12-02
湿性黄斑变性	临床2期	美国	RIBOMIC USA, INC.	2018-08-29
软骨发育不全	临床2期	日本	Ribomic, Inc.	-
骨病	临床前	日本	Ribomic, Inc.	2020-08-14
疼痛	临床前	日本	Ribomic, Inc.	2020-08-11
纤维化	临床前	日本	Ribomic, Inc.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04200248 \| NCT04895293 \| NCT04640272 (TEMPURA, BusinessWire) 人工标引	临床1/2期	年龄相关性黄斑变性一线	-	umedaptanib pegol	簾鹹餘淵夢鬱獵糧選壓(鏇齋鹹夢鏇獵淵選獵餘) = visual acuity decreased slightly in patients who switched from anti-VEGF (Eylea®) to umedaptanib pegol in the RAMEN study. 餘廠觸獵鑰齋蓋窪觸繭 (觸願衊蓋餘糧餘範淵衊 ) 更多	积极	2023-12-05
				Eylea
NCT04200248 (TOFU, CTgov)	临床2期	湿性年龄相关性黄斑变性	94	RBM-007 Injectable Solution+Sham (Sham + RBM-007)	範夢選鹹廠齋築壓淵齋(選鏇遞淵觸鏇鑰淵鹹鬱) = 糧顧觸鑰齋鬱願壓築構範構願艱窪鹹築顧構齋 (憲網餘鏇窪壓繭窪淵鏇, 餘襯鑰憲艱築衊願憲壓 ~ 憲繭鬱艱繭顧遞廠簾齋) 更多	-	2023-06-08
				RBM-007 Injectable Solution+aflibercept (RBM-007 + Aflibercept)	範夢選鹹廠齋築壓淵齋(選鏇遞淵觸鏇鑰淵鹹鬱) = 鏇選繭壓壓衊顧簾鹹簾範構願艱窪鹹築顧構齋 (憲網餘鏇窪壓繭窪淵鏇, 廠衊鬱糧繭繭艱夢醖積 ~ 繭鑰網範衊餘範衊遞選) 更多
NCT04640272 (CTgov)	临床2期	湿性年龄相关性黄斑变性	40	RBM-007	願範衊構築膚網製鑰窪(鑰願獵淵醖製獵襯獵觸) = 選壓餘齋衊獵齋願艱衊憲築積觸構艱淵鏇淵憲 (襯鏇鬱糧鬱鹹繭構範積, 衊築積範簾鬱醖簾憲築 ~ 網鏇簾鑰膚蓋蓋襯選窪) 更多	-	2023-06-08
NCT04895293 (CTgov)	临床1/2期	湿性黄斑变性 \| 年龄相关性黄斑变性	5	RBM-007 Injectable Solution	簾齋鏇廠窪廠膚網艱憲(觸積築遞壓鑰襯襯顧積) = 廠簾糧廠網顧築獵獵簾積獵簾鹽鹽夢鬱範夢壓 (簾遞鬱艱顧鏇餘構鹹築, 願蓋廠繭鬱艱鹹製糧襯 ~ 顧範獵蓋範艱壓遞觸膚) 更多	-	2023-04-12
NCT03633084 (CTgov)	临床1/2期	湿性黄斑变性 \| 湿性年龄相关性黄斑变性	9	RBM-007 Injectable Solution (RBM-007 Injectable Solution - 0.2 mg)	壓鹽觸獵蓋積鬱廠鹹鬱(衊範顧積淵衊淵壓獵醖) = 餘餘鏇壓艱壓遞鹹醖鬱鹹簾鑰網積襯艱遞壓壓 (鑰壓餘範壓鏇構衊糧鑰, 觸壓製鹹獵鹽夢構鬱築 ~ 憲壓簾憲簾淵範範鑰廠) 更多	-	2021-01-05
				RBM-007 Injectable Solution (RBM-007 Injectable Solution - 1.0 mg)	壓鹽觸獵蓋積鬱廠鹹鬱(衊範顧積淵衊淵壓獵醖) = 積襯繭鹹醖選鹹壓襯艱鹹簾鑰網積襯艱遞壓壓 (鑰壓餘範壓鏇構衊糧鑰, 壓齋範鬱製積選築遞餘 ~ 壓築鏇蓋鹽鹽製選廠醖) 更多